HealthDay News — Higher doses of vitamin D3 supplementation up to age 2 years are associated with a decreased risk for internalizing problems in later childhood, according to a study published online May 19 in JAMA Network Open.
Samuel Sandboge, MD, PhD, from the University of Tampere in Finland, and colleagues conducted a secondary analysis of a randomized clinical trial of 346 children to assess the impact of high-dose (1200 IU) vs standard-dose (400 IU) vitamin D3 supplementation during the first 2 years of life on psychiatric symptoms at ages 6 to 8 years.
The researchers found that clinically significant internalizing problems occurred in 5.6 percent of participants in the 1200-IU group vs 11.8% in the 400-IU group (odds ratio, 0.40), when adjusting for sex, birth season, maternal depressive symptoms at birth, and parental single status at follow-up. Among 48 children in the 400-IU group with maternal 25(OH)D concentrations less than 30 ng/mL, higher internalizing problems scores were seen compared with children in the 1200-IU group, including 44 children with maternal 25(OH)D concentrations less than 30 ng/mL (adjusted mean difference, 0.49) and 91 children with maternal concentrations less than 30 ng/mL (adjusted mean difference, 0.37). No differences were seen between the groups for externalizing or total problems.
“This should be interpreted cautiously, however, and be considered only as hypothesis generating given the absence of interactions between maternal 25(OH)D level and supplementation status,” the authors write.
One author reported receiving grants from the Novo Nordisk Foundation.